These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 21687633)
1. Knockdown of MTDH sensitizes endometrial cancer cells to cell death induction by death receptor ligand TRAIL and HDAC inhibitor LBH589 co-treatment. Meng X; Brachova P; Yang S; Xiong Z; Zhang Y; Thiel KW; Leslie KK PLoS One; 2011; 6(6):e20920. PubMed ID: 21687633 [TBL] [Abstract][Full Text] [Related]
2. The oncogene metadherin modulates the apoptotic pathway based on the tumor necrosis factor superfamily member TRAIL (Tumor Necrosis Factor-related Apoptosis-inducing Ligand) in breast cancer. Zhang N; Wang X; Huo Q; Li X; Wang H; Schneider P; Hu G; Yang Q J Biol Chem; 2013 Mar; 288(13):9396-407. PubMed ID: 23408429 [TBL] [Abstract][Full Text] [Related]
3. c-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589. Kauh J; Fan S; Xia M; Yue P; Yang L; Khuri FR; Sun SY PLoS One; 2010 Apr; 5(4):e10376. PubMed ID: 20442774 [TBL] [Abstract][Full Text] [Related]
4. A histone deacetylase inhibitor LBH589 downregulates XIAP in mesothelioma cell lines which is likely responsible for increased apoptosis with TRAIL. Symanowski J; Vogelzang N; Zawel L; Atadja P; Pass H; Sharma S J Thorac Oncol; 2009 Feb; 4(2):149-60. PubMed ID: 19179889 [TBL] [Abstract][Full Text] [Related]
5. Panobinostat Enhances Growth Suppressive Effects of Progestin on Endometrial Carcinoma by Increasing Progesterone Receptor and Mitogen-Inducible Gene-6. Ando H; Miyamoto T; Kashima H; Higuchi S; Ida K; Mvunta DH; Shiozawa T Horm Cancer; 2017 Aug; 8(4):257-267. PubMed ID: 28516379 [TBL] [Abstract][Full Text] [Related]
6. Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma. Chen MC; Huang HH; Lai CY; Lin YJ; Liou JP; Lai MJ; Li YH; Teng CM; Yang CR Oncotarget; 2016 Jan; 7(1):402-17. PubMed ID: 26587975 [TBL] [Abstract][Full Text] [Related]
7. Effects of Histone Deacetylase Inhibitor Panobinostat (LBH589) on Bone Marrow Mononuclear Cells of Relapsed or Refractory Multiple Myeloma Patients and Its Mechanisms. Ma Y; Liu W; Zhang L; Jia G Med Sci Monit; 2017 Oct; 23():5150-5157. PubMed ID: 29080899 [TBL] [Abstract][Full Text] [Related]
8. Pan-histone deacetylase inhibitor panobinostat sensitizes gastric cancer cells to anthracyclines via induction of CITED2. Regel I; Merkl L; Friedrich T; Burgermeister E; Zimmermann W; Einwächter H; Herrmann K; Langer R; Röcken C; Hofheinz R; Schmid R; Ebert MP Gastroenterology; 2012 Jul; 143(1):99-109.e10. PubMed ID: 22465428 [TBL] [Abstract][Full Text] [Related]
9. HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA). Mehdi O; Françoise S; Sofia CL; Urs G; Kevin Z; Bernard S; Igor S; Anabela CD; Dominique L; Eric M; Ali O Pancreatology; 2012; 12(2):146-55. PubMed ID: 22487525 [TBL] [Abstract][Full Text] [Related]
10. Synergistic effects of combined treatment with histone deacetylase inhibitor suberoylanilide hydroxamic acid and TRAIL on human breast cancer cells. Zhou W; Feng X; Han Han ; Guo S; Wang G Sci Rep; 2016 Jun; 6():28004. PubMed ID: 27292433 [TBL] [Abstract][Full Text] [Related]
11. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines. LaBonte MJ; Wilson PM; Fazzone W; Groshen S; Lenz HJ; Ladner RD BMC Med Genomics; 2009 Nov; 2():67. PubMed ID: 19948057 [TBL] [Abstract][Full Text] [Related]
12. Epigenetic modification restores functional PR expression in endometrial cancer cells. Yang S; Xiao X; Jia Y; Liu X; Zhang Y; Wang X; Winters CJ; Devor EJ; Meng X; Thiel KW; Leslie KK Curr Pharm Des; 2014; 20(11):1874-80. PubMed ID: 23888956 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat). Kubo M; Kanaya N; Petrossian K; Ye J; Warden C; Liu Z; Nishimura R; Osako T; Okido M; Shimada K; Takahashi M; Chu P; Yuan YC; Chen S Breast Cancer Res Treat; 2013 Jan; 137(1):93-107. PubMed ID: 23160924 [TBL] [Abstract][Full Text] [Related]
14. The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258. Vallo S; Mani J; Stastny M; Makarević J; Juengel E; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA Invest New Drugs; 2013 Apr; 31(2):265-72. PubMed ID: 22801803 [TBL] [Abstract][Full Text] [Related]
15. HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL. Pathil A; Armeanu S; Venturelli S; Mascagni P; Weiss TS; Gregor M; Lauer UM; Bitzer M Hepatology; 2006 Mar; 43(3):425-34. PubMed ID: 16583461 [TBL] [Abstract][Full Text] [Related]
16. Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells. Edwards A; Li J; Atadja P; Bhalla K; Haura EB Mol Cancer Ther; 2007 Sep; 6(9):2515-24. PubMed ID: 17876048 [TBL] [Abstract][Full Text] [Related]
17. The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity. Woods DM; Woan K; Cheng F; Wang H; Perez-Villarroel P; Lee C; Lienlaf M; Atadja P; Seto E; Weber J; Sotomayor EM; Villagra A Melanoma Res; 2013 Oct; 23(5):341-8. PubMed ID: 23963286 [TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio. Mühlethaler-Mottet A; Flahaut M; Bourloud KB; Auderset K; Meier R; Joseph JM; Gross N BMC Cancer; 2006 Aug; 6():214. PubMed ID: 16930472 [TBL] [Abstract][Full Text] [Related]
19. Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells. Wang G; Edwards H; Caldwell JT; Buck SA; Qing WY; Taub JW; Ge Y; Wang Z PLoS One; 2013; 8(9):e76662. PubMed ID: 24098799 [TBL] [Abstract][Full Text] [Related]
20. Cytoplasmic Metadherin (MTDH) provides survival advantage under conditions of stress by acting as RNA-binding protein. Meng X; Zhu D; Yang S; Wang X; Xiong Z; Zhang Y; Brachova P; Leslie KK J Biol Chem; 2012 Feb; 287(7):4485-91. PubMed ID: 22199357 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]